Mounjaro vs Wegovy: What’s the Difference for Weight Loss?

As weight management and obesity become increasingly central to long-term health and wellbeing, many patients are exploring medication to support their progress. Among the most talked-about options are GLP-1 receptor agonists (glucagon-like peptide-1), including Mounjaro and Wegovy. Interest in these treatments has grown because of their potential effectiveness for weight loss, especially for people who are overweight, have a higher BMI, or live with comorbidities that may improve with weight reduction.

Both treatments work by mimicking the action of the GLP-1 hormone in the body, which helps regulate blood sugar, appetite, and digestion. That said, while their overall approach is similar, their specific active compounds and potential benefits are not the same.

This guide offers a clear comparison of Mounjaro and Wegovy to help patients understand which option may fit best within their weight-loss treatment journey.

A closer look at Mounjaro

Mounjaro, also known by its generic name tirzepatide, is a relatively new GLP-1 treatment developed with a dual action on GLP-1 and GIP receptors (gastric inhibitory polypeptide). This dual mechanism can offer significant advantages, particularly for patients managing weight loss alongside obesity-related conditions such as type 2 diabetes.

Activation of GIP receptors in Mounjaro may promote insulin secretion and support improved blood sugar control, which makes it an especially relevant option for people with diabetes, or those at risk of cardiovascular complications.

For weight loss, tirzepatide works by activating both GLP-1 and GIP receptors. This combination strengthens feelings of fullness, reduces appetite, and slows gastric emptying. In practical terms, patients tend to eat less and feel satisfied for longer, supporting a sustained reduction in overall food intake.

According to a study published in The Lancet (2021), Mounjaro led to a 15% to 20% reduction in body weight in patients with obesity, alongside improvements in HbA1c levels. This dual action is also linked to potential improvements in heart health and a reduction in cardiovascular risks associated with obesity.

A closer look at Wegovy

Wegovy (semaglutide) is a well-established GLP-1 treatment that primarily works by imitating the effects of the body’s natural GLP-1 hormone. It stimulates insulin secretion, slows gastric emptying, and reduces appetite, which supports weight loss.

Wegovy is currently authorised for people with a BMI of 30 or above (obesity), or 27 and above with associated conditions such as hypertension, diabetes, or dyslipidaemia.

According to a key study published in The New England Journal of Medicine (2021), Wegovy resulted in 14% to 17% weight loss in people with obesity, with notable improvements in glycaemic control.

Wegovy has also shown a reduction in the risk of major cardiovascular events in high-risk patients, such as heart attacks or strokes.

Safety and regulatory approvals

Mounjaro and Wegovy are both approved by the MHRA (Medicines and Healthcare Products Regulatory Agency) and the GPhC (General Pharmaceutical Council), ensuring they meet strict standards for safety and effectiveness.

The right choice between Mounjaro and Wegovy will depend on each patient’s health profile, with Mounjaro being particularly suited to patients with diabetes due to its dual mechanism of action.

It is essential to speak with a healthcare professional to determine the most appropriate option based on your needs and your medical history.

Conclusion

Whether you are considering a weight-loss treatment for the first time or looking to explore other options for managing obesity, Mounjaro and Wegovy represent innovative and promising approaches.

By offering targeted interventions that support both weight loss and the management of chronic conditions such as diabetes, these GLP-1 treatments mark real progress in improving health outcomes and quality of life.

Speak to your healthcare professional to build a treatment plan that matches your personal goals and your specific medical needs.

References

• Davies, M., et al. (2022). Tirzepatide for the Management of Type 2 Diabetes: Cardiovascular and Metabolic Benefits. Diabetes Care, 45(6), 1123-1131.
• GPhC. (2022). Guidance on the Use of GLP-1 Receptor Agonists in Weight Management. General Pharmaceutical Council.
• Kristensen, S. L., et al. (2022). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Journal of the American College of Cardiology, 79(4), 306-315.
• MHRA. (2021). Medicines and Healthcare Products Regulatory Agency: Mounjaro and Wegovy Approvals. Medicines and Healthcare products Regulatory Agency.
• Rodriguez, S., et al. (2021). Tirzepatide in Obesity and Weight Loss: Efficacy and Safety. The Lancet, 398(10309), 497-507.
• Rubino, D., et al. (2021). Semaglutide for Weight Loss in Obesity: A Randomized, Controlled Trial. The New England Journal of Medicine, 384(6), 473-484.